Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.

J Thorac Dis · 2023 · PMC10636450 · PMID 37969256

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in the ultimate analysis of the KEYNOTE-789 ( NCT03515837 ) trial, although there was a slight improvement in OS for progressive disease following TKI therapy for metastatic non-squamous NSCLC patients receiving pembrolizumab combined with pemetrexed and platinum chemotherapy compared to the pemetrexed and platinum chemotherapy only group, these improvements did not reach statistical significance according to pre-specified statistical values.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.